News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Pfizer Inc. Says Will Take 1-3 Years To Get HDL-Drug Data
October 21, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK, Oct 20 (Reuters) - Pfizer Inc. (PFE.N: Quote, Profile, Research) on Thursday said it will take one to three years to amass necessary clinical trial data for its cholesterol drug torcetrapib, the most important of its experimental drugs.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Pfizer
MORE ON THIS TOPIC
Drug pricing
Novo Slashes GLP-1 Prices Again, Touts New Weight Loss Data on Heels of Lilly Loss
February 24, 2026
·
3 min read
·
Jef Akst
Cardiovascular disease
Gossamer Nosedives as Late-Stage Failure Plunges PAH Program Into Uncertainty
February 24, 2026
·
2 min read
·
Tristan Manalac
Rare disease
FDA’s Bespoke Pathway To Focus on Gene Editing and RNA-Based Treatments for Rare Diseases
February 23, 2026
·
3 min read
·
Nick Paul Taylor
Weight loss
Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test
February 23, 2026
·
4 min read
·
Annalee Armstrong